Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now NasdaqGM - Nasdaq Real Time Price • USD Cardlytics, Inc. (CDLX) Follow Compare 2.0700 +0.0900 +(4.55%) At close: March 13 at 4:00:02 PM EDT All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Closing Bell Movers: Intel spikes 11% after naming new CEO U.S. equity futures are up marginally – less than 0.1% – in the first hour of the evening session. Wednesday’s trading was once again dominated by the markets trying to parse through the bluster of tariff threats from the White House, with Trump’s 25% tariff on imports of steel and aluminum from all countries taking effect today, even though the cabinet reconsidered its threat to raise tariffs to 50% for Canadian imports of the metals after Canada suspended a new tax on U.S.-bound electricity. T Q4 2024 Cardlytics Inc Earnings Call Q4 2024 Cardlytics Inc Earnings Call Cardlytics Inc (CDLX) Q4 2024 Earnings Call Highlights: Navigating Challenges with Strategic ... Despite a decline in US revenue, Cardlytics Inc (CDLX) leverages strong UK performance and new fintech partnerships to drive future growth. Cardlytics (CDLX) Reports Break-Even Earnings for Q4 Cardlytics (CDLX) delivered earnings and revenue surprises of 100% and 16.35%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock? Cardlytics: Q4 Earnings Snapshot ATLANTA (AP) — Cardlytics, Inc. CDLX) on Wednesday reported a loss of $15.6 million in its fourth quarter. The Atlanta-based company said it had a loss of 31 cents per share. Cardlytics Announces Fourth Quarter and Full Year 2024 Financial Results ATLANTA, March 12, 2025--Cardlytics, Inc. (NASDAQ: CDLX) today announced financial results for the fourth quarter and full year ended December 31, 2024. Cardlytics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) ATLANTA, February 28, 2025--Cardlytics, Inc. (NASDAQ: CDLX) today announced that on February 26, 2025, the Compensation Committee of Cardlytics’ Board of Directors granted an aggregate of 225,800 restricted stock units of Cardlytics to 18 newly hired employees. The restricted stock units were granted as material inducements to employment with Cardlytics in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted under the Cardlytics, Inc. 2022 Inducement Plan (the "2022 Inducement Plan"). Insider Buyers Lose US$57k As Cardlytics Sheds US$23m The recent price decline of 14% in Cardlytics, Inc.'s ( NASDAQ:CDLX ) stock may have disappointed insiders who bought... Cardlytics Announces Timing of Its Fourth Quarter and Full Year 2024 Earnings Release ATLANTA, February 26, 2025--Cardlytics, Inc. (NASDAQ: CDLX) today announced that its financial results for the fourth quarter and full year ending December 31, 2024 will be released on March 12, 2025, after market close. With 49% stake, Cardlytics, Inc. (NASDAQ:CDLX) seems to have captured institutional investors' interest Key Insights Given the large stake in the stock by institutions, Cardlytics' stock price might be vulnerable to their... Is Now The Time To Look At Buying Cardlytics, Inc. (NASDAQ:CDLX)? While Cardlytics, Inc. ( NASDAQ:CDLX ) might not have the largest market cap around , it saw a double-digit share price... Here Is Why Bargain Hunters Would Love Fast-paced Mover Cardlytics (CDLX) Cardlytics (CDLX) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices. Why Is Cardlytics, Inc. (CDLX) Among The Best Advertising Stocks to Buy According to Hedge Funds? We recently compiled a list of the 15 Best Advertising Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Cardlytics, Inc. (NASDAQ:CDLX) stands against the other advertising stocks. Ad spending in 2024 received a significant boost from recurring events such as the US election and the Olympics, […] Estimating The Fair Value Of Cardlytics, Inc. (NASDAQ:CDLX) Key Insights Using the 2 Stage Free Cash Flow to Equity, Cardlytics fair value estimate is US$3.55 With US$3.97 share... Cardlytics Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags Cardlytics ( NASDAQ:CDLX ) Third Quarter 2024 Results Key Financial Results Revenue: US$67.1m (down 15% from 3Q 2023... Cardlytics Inc (CDLX) Q3 2024 Earnings Call Highlights: Navigating Challenges and Leveraging ... Despite revenue declines, Cardlytics Inc (CDLX) focuses on strategic partnerships and innovative pricing models to drive future growth. Cardlytics (CDLX) Reports Q3 Loss, Tops Revenue Estimates Cardlytics (CDLX) delivered earnings and revenue surprises of 54.55% and 19.11%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock? Cardlytics: Q3 Earnings Snapshot ATLANTA (AP) — Cardlytics, Inc. (CDLX) on Wednesday reported a loss of $145.2 million in its third quarter. On a per-share basis, the Atlanta-based company said it had a loss of $2.90. For the current quarter ending in December, Cardlytics said it expects revenue in the range of $62 million to $67 million. Cardlytics Announces Third Quarter 2024 Financial Results ATLANTA, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Cardlytics, Inc. (NASDAQ: CDLX), a digital advertising platform, today announced financial results for the third quarter ended September 30, 2024. "Our third quarter results beat the high end of our guidance, which reflects our relentless focus on addressing our short-term challenges," said Amit Gupta, CEO of Cardlytics. "We maintain that our business transformation will take time, but we believe our priorities to build a more performant network and sca 23andMe Appoints Three New Independent Directors to Board SUNNYVALE, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (the “Company” or “23andMe”), a leading human genetics and preventive health company, today announced the appointments of Andre Fernandez, Jim Frankola, and Mark Jensen, three accomplished and experienced executives, as independent members of the Company’s Board of Directors (the “Board”), effective on October 28, 2024. Each of Mr. Fernandez, Mr. Frankola, and Mr. Jensen have been appointed to serve as members Performance Overview Trailing total returns as of 3/13/2025, which may include dividends or other distributions. Benchmark is S&P 500 Return CDLX S&P 500 YTD -44.20% -6.12% 1-Year -75.93% +6.90% 3-Year -95.58% +31.33%